Previous 10 | Next 10 |
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio - Implements significant cost reduction program - Expects to be sustainably cash flow positive beginning 2H 2022 - Investor conference call and webcast today at 8:00 AM ET (5...
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension - Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: improvement in OHSA #1 in patients ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. U.S. stocks spent most of the week inching up as investors waited for Federal Reserve Chairman Jerome Powell’s Jackson Hole speech on ...
In a choppy day of trading in general, hospitality and lodging stocks provided a consistent source of strength on Tuesday. Optimism that the COVID risk might be subsiding again drove gains in shares of Hyatt Hotels (NYSE:H), Hilton Worldwide (NYSE:HLT), Booking Holdings (NASDAQ:BKNG) and Airb...
The stock of Theravance Biopharma (NASDAQ: TBPH) is losing ground after a phase 2 trial failed to meet its primary endpoint. Investors disappointed with the company's mid-stage pipeline asset sent the stock down 34.4% as of 2:28 p.m. EDT on Tuesday. Sales of Theravance Biopharma...
Gainers: Takung Art (NYSE:TKAT) +48%. Triple-S Management (NYSE:GTS) +45%. KLX Energy (NASDAQ:KLXE) +25%. New Oriental Education (NYSE:EDU) +26%. SkyWater Technology (NASDAQ:SKYT) +25%. Sentage (NASDAQ:SNTG) +24%. Bio-Path Holdings (NASDAQ:BPTH) +20%. TuSimple (NASDAQ:TSP) +20%. CynergisTek (...
Gainers: Triple-S Management (NYSE:GTS) +45%, Bio-Path (NASDAQ:BPTH) +21%, Reviva Pharmaceuticals (NASDAQ:RVPH) +21%, XTL Biopharmaceuticals (NASDAQ:XTLB) +13%, Protara Therapeutics (NASDAQ:TARA) +12%. Losers: Theravance Biopharma (NASDAQ:TBPH) ...
Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis - Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: change in the total Mayo score at week eigh...
Seth Klarman’s 13F portfolio value decreased from $12.56B to $12.33B this quarter. Baupost Group increased Micron Technology and Facebook while dropping Fox Corp. The portfolio continues to be heavily concentrated with the top three positions accounting for ~32% of the 13F ...
Image source: The Motley Fool. Theravance Biopharma, inc (NASDAQ: TBPH) Q2 2021 Earnings Call Aug 3, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Theravance Biopharma, inc (TBPH) Q2 2021 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...